Skip to main content
. 2020 May 4;20:119. doi: 10.1186/s12890-020-1153-7

Table 2.

Summary of treatment-emergent AEs

n, % BAT/FF 300/100
(n = 42)
Placebo
(n = 20)
Any AE 16 (38) 7 (35)
 Drug-related AE 6 (14) 0
AE leading to discontinuation 2 (5) 0
Serious AE 1 (2)a 0
 Fatal AE 0 0
AEs reported in ≥2 subjects in any treatment group by preferred termb
 Dysgeusia 4 (10) 0
 Nasopharyngitis 3 (7) 1 (5)
 Diarrhea 3 (7) 0
 Cough 2 (5) 0

AE adverse event, BAT/FF 300/100 batefenterol/fluticasone furoate 300/100 μg

aThe single serious AE developed post treatment. bSee Table S5 for all AEs experienced during the study